Last reviewed · How we verify
EpiCept-NP-1 Cream
EpiCept-NP-1 Cream is a topical analgesic that works by blocking the production of substance P, a neuropeptide involved in pain transmission.
EpiCept-NP-1 Cream is a topical analgesic that works by blocking the production of substance P, a neuropeptide involved in pain transmission. Used for Moderate to severe pain in patients with postherpetic neuralgia.
At a glance
| Generic name | EpiCept-NP-1 Cream |
|---|---|
| Sponsor | EpiCept Corporation |
| Drug class | Topical analgesic |
| Target | Neutral endopeptidase (NEP) |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the enzyme neutral endopeptidase (NEP), EpiCept-NP-1 Cream reduces the levels of substance P in the spinal cord, leading to a decrease in pain perception. This mechanism is thought to be responsible for its analgesic effects.
Approved indications
- Moderate to severe pain in patients with postherpetic neuralgia
Common side effects
- Skin irritation
- Pruritus
- Application site reaction
Key clinical trials
- Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients (PHASE3)
- A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN) (PHASE2)
- A Study of the Efficacy and Safety of Amitriptyline/Ketamine Topical Cream in Patients With Diabetic Peripheral Neuropathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EpiCept-NP-1 Cream CI brief — competitive landscape report
- EpiCept-NP-1 Cream updates RSS · CI watch RSS
- EpiCept Corporation portfolio CI